TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

LEVEMIR INNOLET

INSULIN DETEMIR RECOMBINANT
Approved 2005-06-16
4
Indications
--
Phase 3 Trials
20
Years on Market

Details

Status
Discontinued
First Approved
2005-06-16
Routes
SUBCUTANEOUS
Dosage Forms
INJECTABLE

Companies

Active Ingredient: INSULIN DETEMIR RECOMBINANT

LEVEMIR INNOLET Approval History

Loading approval history...

What LEVEMIR INNOLET Treats

4 FDA approvals

Originally approved for its first indication in 2005 . Covers 4 distinct patient populations.

  • Other (4)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LEVEMIR INNOLET FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.